| scholarly article | Q13442814 |
| P50 | author | Hisashi Yamanaka | Q88712489 |
| Kazuyoshi Saito | Q98839521 | ||
| Tsutomu Takeuchi | Q40949081 | ||
| P2093 | author name string | Yoshiya Tanaka | |
| Sang Joon Lee | |||
| Takeo Sakurai | |||
| Yoshihiro Nambu | |||
| Hideo Ohtsubo | |||
| P2860 | cites work | Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score | Q24817087 |
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | Q33885648 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial | Q35605449 | ||
| Physicochemical characterization of Remsima | Q36213623 | ||
| A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study | Q37206622 | ||
| A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study | Q37206628 | ||
| Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study | Q37380288 | ||
| Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers | Q41930269 | ||
| A simplified disease activity index for rheumatoid arthritis for use in clinical practice | Q44321551 | ||
| Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases | Q44616013 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| Measurement of patient outcome in arthritis | Q56879288 | ||
| The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial | Q74455184 | ||
| Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? | Q77341371 | ||
| P433 | issue | 6 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 817-824 | |
| P577 | publication date | 2015-04-02 | |
| P1433 | published in | Modern Rheumatology | Q15752709 |
| P1476 | title | Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis | |
| P478 | volume | 25 |
| Q36303459 | A practical guide about biosimilar data for health care providers treating inflammatory diseases |
| Q33881234 | A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. |
| Q52651099 | Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. |
| Q26746634 | Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation |
| Q47688424 | Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm |
| Q90083372 | Biosimilars versus biologics for inflammatory conditions |
| Q38676104 | CT-P13 in the treatment of rheumatoid arthritis. |
| Q47418286 | Comparative effectiveness of the biosimilar CT-P13. |
| Q28066776 | Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases |
| Q88698802 | Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust |
| Q39371316 | Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review |
| Q38960108 | Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases |
| Q92680304 | Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice |
| Q58798380 | Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies |
| Q57174419 | Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know? |
| Q39430200 | Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. |
| Q33840949 | Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician |
| Q26749525 | Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health |
| Q89460342 | The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases |
| Q26766515 | The changing landscape of biosimilars in rheumatology |
| Q30397234 | The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis |
| Q38591244 | The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. |
Search more.